DeepMed Research

Henan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1977-01-01

Employees: -

Market Cap: -

Website: http://www.anti-cancer.com.cn

Clinical Trials

PI3Kδ Inhibitor Parsaclisib Combined with Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 1

Terminated

Conditions: Peripheral T-Cell Lymphoma

Interventions: Drug: Parsaclisib
Drug: Chidamide

First Posted Date: 2021-10-19

Last Posted Date: 2025-03-26

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 12

Registration Number: NCT05083208

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Placebo+endocrine therapy
Drug: Capecitabine+endocrine therapy

First Posted Date: 2021-09-30

Last Posted Date: 2024-11-04

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 1979

Registration Number: NCT05063136

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer

Interventions: Other: nonintervention

First Posted Date: 2021-08-26

Last Posted Date: 2022-04-01

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 300

Registration Number: NCT05023720

Locations: 🇨🇳
Henan cancer hosiptal, Zhengzhou, Henan, China

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

Phase 2

Conditions: Esophageal Neoplasms

Interventions: Drug: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib
Drug: Paclitaxel + Cisplatin + TQB2450 injection

First Posted Date: 2021-08-19

Last Posted Date: 2021-08-19

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 48

Registration Number: NCT05013697

Locations: 🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
AnYang Tumor Hospital, Anyang, Henan, China

and more 2 locations

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Phase 2

Conditions: Advanced Gastric Carcinoma

Interventions: Drug: camrelizumab
Drug: Apatinib Mesylate

First Posted Date: 2021-07-01

Last Posted Date: 2021-07-01

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT04948125

Locations: 🇨🇳
Henan cancer hospital/The affiliated Cancer Hospital of ZhengZhou university, Henan, China

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Phase 2

Recruiting

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Rituximab, Lenalidomide, Zanubrutinib
Drug: Lenalidomide
Drug: Lenalidomide, Zanubrutinib

First Posted Date: 2021-06-24

Last Posted Date: 2021-06-24

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT04938297

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer

Phase 2

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Camrelizumab Plus Apatinib

First Posted Date: 2021-05-25

Last Posted Date: 2021-12-08

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 38

Registration Number: NCT04901754

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Not Applicable

Active, not recruiting

Conditions: Gastric Cancer
Adenocarcinoma of Esophagogastric Junction

Interventions: Drug: TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine

First Posted Date: 2021-05-19

Last Posted Date: 2024-07-08

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 25

Registration Number: NCT04891900

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Chemotherapy
Immune Checkpoint Inhibitor
Locally Advanced Gastric Carcinoma

Interventions: Drug: FLOT combined with toripalimab

First Posted Date: 2021-05-18

Last Posted Date: 2024-06-06

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT04891016

Locations: 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Not Applicable

Conditions: Leptomeningeal Metastasis
NSCLC
Brain Metastases

Interventions: Drug: LM-first line treatment
Drug: LM-second line treatment
Drug: almonertinib

First Posted Date: 2021-03-03

Last Posted Date: 2021-08-31

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT04778800

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy